Industry Insights
-
Europe's ATMP Opportunity Still Requires Local Navigation
8/27/2026
European nations offer a welcoming environment for clinical-phase cell and gene therapies. Don't assume the same flexibility carries through to commercialization.
-
The Unspoken Truth About Cell Therapy Product Understanding
8/27/2026
Developers often discover important attributes after it's too late to act on them. A well-designed program asks what's needed for commercialization and works backward.
-
Overcoming Recovery Challenges In AAV Production
8/26/2026
Siren Biotechnology's SVP of vector development, Nathalie Clément, Ph.D., explains the challenge of purifying AAV capsids and the ways developers are optimizing vector recovery.
-
In Vivo CAR T Needs More Than Better Cell Engineering
8/26/2026
In vivo CAR T’s potential to expand access and simplify manufacturing hinges on targeted LNP delivery and solving the durability challenge.
-
Enzyme Activity As A Surrogate Potency Marker In Cell Therapy
8/26/2026
When measuring cell therapy potency, biochemical assays can provide a rapid alternative to the time- and material-consuming standard of cell-based assays.
-
Implementing And Optimizing Your eQMS
8/25/2026
This article addresses everything that follows the signed contract for an eQMS: how a system is configured, validated, adopted, and maintained.
-
Novel Approach To Cancer Explores Severing Its Genetic Supply Line
8/25/2026
Gene ablation represents an important and novel approach to treating cancer. One company is focusing on disabling the NRF2 gene to starve cancer cells.
-
Choosing Analytical Technologies At The Right Stage Of Development
8/24/2026
Take a beat before investing in the latest analytical tools. Capability and sensitivity come at a cost. Depending on your phase, you might not need it just yet.
-
CDMO Selection For Small Biotech: Amit Jain On Avoiding Costly Transfers
8/20/2026
Make smarter outsourcing decisions early. Reduce the risk of costly tech transfers, evaluate capacity needs, speed development timelines, and strengthen manufacturing partnerships.
-
Reimagining Solid Tumor Immunotherapy With SRC-3-Edited Tregs
8/20/2026
CoRegen’s investigational autologous cell therapy, CRG-150, is designed to disrupt tumor-driven immune suppression by knocking out SRC-3 in Tregs, potentially exposing solid tumors to the patient’s own immune response without lymphodepletion.